Shuanghuanglian Injection Veterinary Grade API for sterile parenteral solutions is received as a concentrated aqueous extract standardized to multiple phenolic markers—baicalin, chlorogenic acid, and forsythin—rather than a single chemically defined entity, which means batch-to-batch blending in the formulation suite must be controlled by assay-based adjustment rather than gravimetric dilution alone. On a commercial aseptic filling line, the extract is diluted with Water for Injection to a final concentration equivalent to 1.0 g crude drug per mL, with extract solids typically in the range of 8–12% w/v; the finished injection is then prefiltered through 0.45 μm polyethersulfone membranes and sterilized through 0.22 μm membranes before filling into 10 mL, 100 mL, or 500 mL Type II glass vials. pH is adjusted with 0.1 N sodium hydroxide or citric acid to pH 6.5–7.5, because baicalin degrades rapidly below pH 5.5 and chlorogenic acid oxidation accelerates above pH 8.0; nitrogen sparging during mixing and holding at 4–8°C before sterile filtration are standard controls observed in toll manufacture. The downstream production process therefore consists of chilled extract dilution, pH adjustment, activated carbon clarification where permitted, 0.45 μm pre-filtration, 0.22 μm sterilizing-grade filtration, aseptic filling, and terminal sterilization only when forced degradation data confirm no loss of marker compounds. Compliance for export batches references USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, 21 CFR 211 aseptic processing, and VICH GL18(R2) residue depletion for food-producing species. The formulation addition ratio in the final solution is defined not by dry solids alone but by marker content; technical agreements commonly specify baicalin not less than 5 mg/mL, chlorogenic acid not less than 0.6 mg/mL, and forsythin not less than 3 mg/mL, with sodium metabisulfite at 0.5–2.0% w/v where the target market authorizes antioxidant use. Terminal finished product types are single-dose 10 mL vials for nursery pigs, 100 mL multi-dose vials for grow-finish herds, and 500 mL infusion bottles for clinical veterinary hospitals; the primary use is supportive therapy in porcine respiratory disease complex, where secondary bacterial infection and viral load reduction are targeted, not replacement of antimicrobial therapy.

Why Does Baicalin Retention in Drinking-Water Soluble Powder Collapse Above 60% RH?

Broiler integrators and layer operations use Shuanghuanglian Injection Veterinary Grade API in drinking-water soluble powders because medication via nipple drinkers avoids feed intake depression during respiratory outbreaks. The powder is formulated with the API extract at 40–60% w/w, dextrose monohydrate or maltodextrin DE10–15 as carrier at 35–55% w/w, and sodium citrate at 2–5% w/w to buffer pH in the stock solution. The addition ratio at the farm gate is typically 0.3–1.0 g powder per L drinking water for 5–7 days, but manufacturer batch records show that hard water above 300 mg/L CaCO₃ equivalent reduces baicalin solubility, requiring stock solution preparation in softened water. Compliance for non-sterile oral powders references USP <61> and USP <62> microbial limits, USP <731> loss on drying, ISO 6496:1999 moisture determination, and heavy metal limits by atomic absorption spectrophotometry. The downstream production process uses spray drying of the concentrated extract onto the carrier at inlet temperature 160–180°C and outlet temperature 80–85°C, followed by low-shear V-blending for 15–20 min and immediate packaging in aluminum-laminated sachets at ≤40% RH because the amorphous phenolic matrix is hygroscopic and baicalin retention collapses above 60% RH; caking and discoloration appear within 48 h when barrier packaging is damaged. Terminal finished product types are 100 g sachets, 1 kg jars, and 25 kg drums with silica gel desiccant; the powder must not be premixed with acidifiers or chlorine-releasing disinfectants in the drinking water line because low pH and free chlorine accelerate phenolic oxidation.

Thermal Exposure During Pellet Conditioning Reduces Marker Recovery More Than Mixing Shear

Feed mills preparing Shuanghuanglian Injection Veterinary Grade API as a concentrated premix for swine and poultry rations must account for the fact that the phytogenic extract is not a free-flowing crystalline solid; it is blended into a carrier system before dispersion into complete feed. A representative concentrated premix contains 10–20% w/w API extract, 70–85% w/w calcium carbonate or wheat middling carrier, and 2–5% w/w hydrophobic silica to improve flow, with final complete feed inclusion at 200–500 g premix per 1,000 kg feed. The addition ratio at the complete feed level is therefore 0.02–0.05% w/w of the original API extract, and marker homogeneity must be verified by assay of baicalin and forsythin in 10 grab samples with relative standard deviation below 5%. The downstream production process uses a ribbon blender with working capacity 500–2,000 L and mixing time 10–15 min; microencapsulation with ethyl cellulose or maltodextrin is often required before pellet conditioning, because steam conditioning at 70–85°C for 30–60 s causes greater marker loss than dry mixing shear alone. Compliance for feed premixes references ISO 6497:2002 sampling, ISO 6496:1999 moisture determination, heavy metal limits by atomic absorption spectrophotometry, and VICH GL11 impurity assessment where the premix is registered as a veterinary medicinal feed additive. Terminal finished product types are 20 kg multi-wall bags and 25 kg drums for feed mills; the premix is not intended for direct feeding and must be diluted sequentially in a two-step mixing program to avoid segregation of the high-density carrier and low-density extract granules.

A compliance matrix across the principal dosage forms is provided below:

Dosage form	Primary reference / clause	Test designation	Critical process boundary
Injectable solution	21 CFR 211, USP <1>	USP <71>, USP <85>, USP <788>	pH 6.5–7.5, 0.22 μm filtration
Soluble powder	USP <61>, USP <62>	USP <731>, ISO 6496:1999	≤40% RH packaging, moisture ≤5%
Feed premix	ISO 6497:2002	ISO 6496:1999, AAS heavy metals	pellet conditioning ≤85°C, mixing CV <5%
Oral granules	USP <795>, GMP	USP <731>	fluid bed drying ≤65°C, moisture ≤3%
Tablet / capsule	USP <2040>, USP <905>	USP <711>	compression force 10–20 kN, friability ≤1.0%
Oral solution	USP <1231>	USP <61>, USP <62>	pH 6.0–7.0, chlorine-free water

When oral granules are specified for pre-weaning calves or piglets, Shuanghuanglian Injection Veterinary Grade API is converted into a free-flowing granule rather than a powder because the bitter phenolic fraction reduces voluntary intake when drenched as a suspension. In a typical wet granulation process, the API extract is incorporated at 25–40% w/w on dry solids, mannitol or lactose monohydrate at 50–70% w/w, povidone binder at 3–5% w/w, and citric acid at 1–2% w/w for palatability masking; the dosage for neonatal calves is generally 0.5–1.0 g of finished granules per 10 kg body weight every 12 h, although published pharmacokinetic data for this specific configuration is limited and field regimens are often adjusted by herd veterinarians. The downstream production process uses a high-shear granulator with impeller speed 200–300 rpm and chopper speed 1,500–3,000 rpm, followed by fluidized-bed drying at inlet temperature 55–65°C to a final moisture below 3%; oversize granules are passed through a 1.2 mm mesh and recycled, while fines below 150 μm are re-granulated. Compliance for non-sterile granules references USP <795> nonsterile compounding where applicable, USP <731> loss on drying, microbial limit tests USP <61> and USP <62>, and VICH GL18(R2) withdrawal period assessment for food-producing animals. Terminal finished product types are 25 g jars, 50 g high-density polyethylene bottles, and 500 g bulk containers for veterinary clinics; the granules should not be co-administered with tannin-rich feeds because phenolic complexation reduces absorption.

When a Veterinary Tablet or Capsule Is Required Despite Phytogenic Compression Constraints

Compressed tablets and capsules containing Shuanghuanglian Injection Veterinary Grade API appear in some non-food-producing animal pharmacies and export lines, but published formulation data for this specific configuration is limited because the hygroscopic extract has poor flow and high compactibility defects. Where a tablet is required, the API extract is granulated by dry compaction with microcrystalline cellulose at 20–40% w/w, crospovidone at 3–5% w/w, and magnesium stearate at 0.5–1.0% w/w; the API extract loading in the tablet core is held at 20–30% w/w to avoid sticking and capping on rotary presses. For capsules, the granulated or dry-blended fill typically contains 30–45% w/w API extract, lactose monohydrate or mannitol at 40–60% w/w, and colloidal silicon dioxide at 0.5–1.5% w/w, filled into hypromellose capsules at 0.3–0.5 g fill weight. The downstream production process uses roll compaction at specific roll pressure 30–50 kN/cm, milling through a 1.0 mm screen, tableting on a 16–24 station rotary press with compression force 10–20 kN, or tamping-pin capsule filling at 20,000–60,000 capsules per hour; wet granulation is avoided because the extract becomes tacky above 25% moisture and blocks screens. Compliance references USP <2040> disintegration, USP <711> dissolution, USP <905> uniformity of dosage units, and ICH Q3D elemental impurities where the dosage form is registered outside China. Terminal finished product types are 0.5 g compressed tablets, 0.3 g capsules, and alu-alu blister packs to protect against moisture; magnesium stearate above 1.0% w/w and humidity above 50% RH during compression are the two most frequent causes of dissolution slowdown and punch sticking.

Automated Poultry Medicator Stock Solutions and pH-Dependent Phenolic Stability

Oral solution dosage forms of Shuanghuanglian Injection Veterinary Grade API are manufactured for poultry and swine producers who prefer medicator dosing because stock solutions can be metered without in-feed mixing. The stock solution is formulated with the API extract at 10–20% v/v, purified water at 75–85% v/v, potassium sorbate at 0.1–0.2% w/v, and citric acid or sodium citrate to achieve a final pH of 6.0–7.0; the addition ratio at the drinker line is usually 1:1,000 through a dosing pump, yielding 0.5–1.0 mL finished solution per L drinking water. The downstream production process involves chilled mixing at 15–20°C, filtration through 5 μm and 1 μm polypropylene cartridges, filling into high-density polyethylene bottles, and nitrogen flushing where headspace oxygen is controlled below 2%. Compliance references USP <1231> water for pharmaceutical purposes, USP <61> and USP <62> microbial limits, and 21 CFR 211 where the product is registered as a veterinary drug. Terminal finished product types are 500 mL, 1 L, and 5 L HDPE containers with tamper-evident caps; the solution should not be mixed with chlorinated water above 1 ppm free chlorine because phenolic oxidation produces dark precipitates and reduces baicalin content.